We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » Biovail, GSK Accused of Generic Wellbutrin Delay
Biovail, GSK Accused of Generic Wellbutrin Delay
December 18, 2009
An employee benefit plan has filed a motion to certify a class action against Biovail and GlaxoSmithKline (GSK), alleging the companies conspired to delay
entry of a generic form of the antidepressant Wellbutrin XL.